share_log
Breakings ·  Sep 27 12:38

Sihuan Pharm (00460) announced that the group has signed an exclusive sales agreement with south korea biopharmaceutical company Hugel, Inc. (Hugel) regarding the injection of type A botulinum toxin (commodity name: Letaibo, specifications: 100U and 50U). Both parties of the agreement have unanimously agreed to renew it until the end of 2030.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment